Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

HIV therapy by a combination of broadly neutralizing antibodies in humanized mice


Human antibodies to human immunodeficiency virus-1 (HIV-1) can neutralize a broad range of viral isolates in vitro and protect non-human primates against infection1,2. Previous work showed that antibodies exert selective pressure on the virus but escape variants emerge within a short period of time3,4. However, these experiments were performed before the recent discovery of more potent anti-HIV-1 antibodies and their improvement by structure-based design5,6,7,8,9. Here we re-examine passive antibody transfer as a therapeutic modality in HIV-1-infected humanized mice. Although HIV-1 can escape from antibody monotherapy, combinations of broadly neutralizing antibodies can effectively control HIV-1 infection and suppress viral load to levels below detection. Moreover, in contrast to antiretroviral therapy10,11,12, the longer half-life of antibodies led to control of viraemia for an average of 60 days after cessation of therapy. Thus, combinations of potent monoclonal antibodies can effectively control HIV-1 replication in humanized mice, and should be re-examined as a therapeutic modality in HIV-1-infected individuals.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Figure 1: Monotherapy using broadly neutralizing antibodies in HIV-1 YU2 -infected humanized mice.
Figure 2: HIV therapy by a combination of three (tri-mix) or five (penta-mix) broadly neutralizing antibodies in HIV-1 YU2 -infected humanized mice.
Figure 3: Viral rebound in HIV-1 YU2 -infected humanized mice after cessation of antibody therapy.


  1. Hessell, A. J. et al. Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nature Med. 15, 951–954 (2009)

    CAS  Article  Google Scholar 

  2. Mascola, J. R. et al. Protection of macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J. Virol. 73, 4009–4018 (1999)

    CAS  PubMed  PubMed Central  Google Scholar 

  3. Wei, X. et al. Antibody neutralization and escape by HIV-1. Nature 422, 307–312 (2003)

    CAS  ADS  Article  Google Scholar 

  4. Poignard, P. et al. Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivo. Immunity 10, 431–438 (1999)

    CAS  Article  Google Scholar 

  5. Diskin, R. et al. Increasing the potency and breadth of an HIV antibody by using structure-based rational design. Science 334, 1289–1293 (2011)

    CAS  ADS  Article  Google Scholar 

  6. Scheid, J. F. et al. Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science 333, 1633–1637 (2011)

    CAS  ADS  Article  Google Scholar 

  7. Walker, L. M. et al. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 477, 466–470 (2011)

    CAS  ADS  Article  Google Scholar 

  8. Walker, L. M. et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326, 285–289 (2009)

    CAS  ADS  Article  Google Scholar 

  9. Wu, X. et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 329, 856–861 (2010)

    CAS  ADS  Article  Google Scholar 

  10. Choudhary, S. K. et al. Suppression of human immunodeficiency virus type 1 (HIV-1) viremia with reverse transcriptase and integrase inhibitors, CD4+ T-cell recovery, and viral rebound upon interruption of therapy in a new model for HIV treatment in the humanized Rag2−/−γc−/− mouse. J. Virol. 83, 8254–8258 (2009)

    CAS  Article  Google Scholar 

  11. Nischang, M. et al. Humanized mice recapitulate key features of HIV-1 infection: A novel concept using long-acting anti-retroviral drugs for treating HIV-1. PLoS ONE 7, e38853 (2012)

    CAS  ADS  Article  Google Scholar 

  12. Denton, P. W. et al. Generation of HIV latency in humanized BLT mice. J. Virol. 86, 630–634 (2012)

    CAS  Article  Google Scholar 

  13. Weiss, R. A. Special anniversary review: twenty-five years of human immunodeficiency virus research: successes and challenges. Clin. Exp. Immunol. 152, 201–210 (2008)

    CAS  Article  Google Scholar 

  14. Finzi, D. & Siliciano, R. F. Viral dynamics in HIV-1 infection. Cell 93, 665–671 (1998)

    CAS  Article  Google Scholar 

  15. Arts, E. J. & Hazuda, D. J. HIV-1 antiretroviral drug therapy. Cold Spring Harb. Persp. Med. 2, a007161 (2012)

    Google Scholar 

  16. Traggiai, E. et al. Development of a human adaptive immune system in cord blood cell-transplanted mice. Science 304, 104–107 (2004)

    CAS  ADS  Article  Google Scholar 

  17. Brehm, M. A. et al. Parameters for establishing humanized mouse models to study human immunity: analysis of human hematopoietic stem cell engraftment in three immunodeficient strains of mice bearing the IL2rγnull mutation. Clin. Immunol. 135, 84–98 (2010)

    CAS  Article  Google Scholar 

  18. Baenziger, S. et al. Disseminated and sustained HIV infection in CD34+ cord blood cell-transplanted Rag2−/−γc−/− mice. Proc. Natl Acad. Sci. USA 103, 15951–15956 (2006)

    CAS  ADS  Article  Google Scholar 

  19. Ince, W. L. et al. Evolution of the HIV-1 env gene in the Rag2−/−γC−/− humanized mouse model. J. Virol. 84, 2740–2752 (2010)

    CAS  Article  Google Scholar 

  20. McLellan, J. S. et al. Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature 480, 336–343 (2011)

    CAS  ADS  Article  Google Scholar 

  21. Klein, F. et al. Broad neutralization by a combination of antibodies recognizing the CD4 binding site and a new conformational epitope on the HIV-1 envelope protein. J. Exp. Med. 209, 1469–1479 (2012)

    CAS  Article  Google Scholar 

  22. Kwong, P. D. et al. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 393, 648–659 (1998)

    CAS  ADS  Article  Google Scholar 

  23. Mehandru, S. et al. Adjunctive passive immunotherapy in human immunodeficiency virus type 1-infected individuals treated with antiviral therapy during acute and early infection. J. Virol. 81, 11016–11031 (2007)

    CAS  Article  Google Scholar 

  24. Trkola, A. et al. Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nature Med. 11, 615–622 (2005)

    CAS  Article  Google Scholar 

  25. Nimmerjahn, F. & Ravetch, J. V. Antibody-mediated modulation of immune responses. Immunol. Rev. 236, 265–275 (2010)

    CAS  Article  Google Scholar 

  26. Ng, C. T. et al. Passive neutralizing antibody controls SHIV viremia and enhances B cell responses in infant macaques. Nature Med. 16, 1117–1119 (2010)

    CAS  Article  Google Scholar 

  27. Johnson, P. R. et al. Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys. Nature Med. 15, 901–906 (2009)

    CAS  Article  Google Scholar 

  28. Balazs, A. B. et al. Antibody-based protection against HIV infection by vectored immunoprophylaxis. Nature 481, 81–84 (2012)

    CAS  ADS  Article  Google Scholar 

  29. Rouet, F. et al. Transfer and evaluation of an automated, low-cost real-time reverse transcription-PCR test for diagnosis and monitoring of human immunodeficiency virus type 1 infection in a West African resource-limited setting. J. Clin. Microbiol. 43, 2709–2717 (2005)

    CAS  Article  Google Scholar 

  30. Mouquet, H. Complex-type N-glycan recognition by potent broadly-neutralizing HIV antibodies. Proc. Natl Acad. Sci. USA (in the press)

  31. Billerbeck, E. et al. Development of human CD4+FoxP3+ regulatory T cells in human stem cell factor-, granulocyte-macrophage colony-stimulating factor-, and interleukin-3-expressing NOD-SCID IL2Rγnull humanized mice. Blood 117, 3076–3086 (2011)

    CAS  Article  Google Scholar 

  32. Zhang, Y. J. et al. Envelope-dependent, cyclophilin-independent effects of glycosaminoglycans on human immunodeficiency virus type 1 attachment and infection. J. Virol. 76, 6332–6343 (2002)

    CAS  Article  Google Scholar 

  33. Scheid, J. F. et al. Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature 458, 636–640 (2009)

    CAS  ADS  Article  Google Scholar 

  34. Tiller, T. et al. Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning. J. Immunol. Methods 329, 112–124 (2008)

    CAS  Article  Google Scholar 

  35. Montefiori, D. C. Evaluating neutralizing antibodies against HIV, SIV, and SHIV in luciferase reporter gene assays. Curr. Protoc. Immunol. Ch. 12, Unit 12 11. (2005)

  36. Li, M. et al. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J. Virol. 79, 10108–10125 (2005)

    CAS  Article  Google Scholar 

Download references


We thank R. Kaiser for analysing viral loads of reference HIV-1 samples and N. N. Freund for producing YU2 gp120. We thank B. Flatley, T. Friling, H. Gao, S. Sell and S. Hinklein for assistance and technical support, M. Suarez-Farinas for advice on statistical analysis, and M. Babayeva for helping with antibody t1/2 estimation. M.C.N. and F.K. have a pending patent application for the antibody 3BC176 and M.C.N., P.J.B. and H.M. for the antibody 10-1074 with the United States Patent and Trademark Office. These reagents are available with a Material Transfer Agreement. F.K. (KL 2389/1-1), M.D. (DO 1450/1-1) and E.B. (BI 1422/1-1) were supported by the German Research Foundation (DFG). H.G., C.G. and R.-B.I. were supported by The German National Academic Foundation. M.S.S. was supported by the Bill and Melinda Gates Foundation’s Comprehensive Antibody Vaccine Immune Monitoring Consortium, grant number 1032144. A.P. is a recipient of a Liver Scholar Award from the American Liver Foundation. This work was supported in part by CAVD grant OPP1033115 from the Bill and Melinda Gates Foundation to M.C.N., in part by NIAID 1UM1AI100663 to M.C.N. and NIH grant AI081677 to M.C.N. M.C.N., P.J.B. and P.D.B. are HHMI investigators.

Author information

Authors and Affiliations



F.K., A.H.-S. and J.A.H. planned and performed experiments and wrote the manuscript. H.G., J.F.H., S.B., H.M., L.A.S., R.D., A.A., T.Z., M.D., E.B., R.N.L., C.G., P.M.M., R.-B.I., T.R.E. and M.S.S. performed experiments. P.D.B., P.J.B., J.V.R. and A.P. provided reagents, advice and edited the manuscript. M.C.N. planned experiments and wrote the manuscript.

Corresponding author

Correspondence to Michel C. Nussenzweig.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Supplementary information

Supplementary Information

This file contains Supplementary Figures 1-13 and Supplementary Tables 1-3. (PDF 1798 kb)

PowerPoint slides

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Klein, F., Halper-Stromberg, A., Horwitz, J. et al. HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. Nature 492, 118–122 (2012).

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI:

Further reading


By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing